sc 58125 has been researched along with Myocardial Infarction in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Birnbaum, Y; Kodakandla, M; Ling, S; Nanhwan, MK; Nylander, S; Ye, Y | 1 |
| Atar, S; Birnbaum, Y; Huang, MH; Lin, Y; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
2 other study(ies) available for sc 58125 and Myocardial Infarction
| Article | Year |
|---|---|
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Aspirin; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Enzyme Induction; Lipoxins; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Receptor, Adenosine A2A; Ticagrelor; Ticlopidine; Triazoles; Up-Regulation | 2014 |
Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Synergism; Drug Therapy, Combination; Gene Expression Regulation; Heptanoic Acids; Hypoglycemic Agents; Inositol Polyphosphate 5-Phosphatases; Male; Myocardial Infarction; Nitric Oxide Synthase Type III; Oncogene Protein v-akt; Phospholipases A; Phospholipases A2; Phosphoric Monoester Hydrolases; Phosphorylation; Pioglitazone; PTEN Phosphohydrolase; Pyrazoles; Pyrroles; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Thiazolidinediones | 2006 |